Therapeutics targeting ERBB receptors in breast cancer include the humanized anti-ErbB2 antibody trastuzumab (Herceptin) and the tyrosine kinase inhibitor, lapatinib which are efficacious and widely used in the clinic. The gene discussed is ERBB2; the disease is breast cancer.